Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaru Shibata

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Physical Review Letters|May 2, 2025
Accessing Universal Relations of Binary Neutron Star Waveforms in Massive Scalar-Tensor TheoryAlan Tsz-Lok Lam, Yong Gao, Hao-Jui Kuan, et al.
International Journal of Cardiology|July 6, 2016
Impact of postconditioning with lactate-enriched blood on in-hospital outcomes of patients with ST-segment elevation myocardial infarctionTakashi Koyama, Masahito Munakata, Takashi Akima, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 8, 2011
Hemostatic treatment using factor VIII concentrates for neutralizing high-responding inhibitors prior to CVAD insertion for immune-tolerance induction therapyMasaru Shibata, Takashi Nakagawa, Shinji Akioka, et al.
JACC. Case Reports|June 20, 2025
Discordant Antithrombotic Effects of Apixaban in Fibrillating Left Atria vs Post-Myocardial Infarction Left Ventricular AneurysmYusuke Yamazaki, Toru Egashira, Mayu Nozawa, et al.
Blood|May 16, 2002
A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivationKeiji Nogami, Midori Shima, Katsumi Nishiya, et al.
Stem Cells (Dayton, Ohio)|July 7, 2007
Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitorsHideto Matsui, Masaru Shibata, Brian Brown, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2010
LIL3, a light-harvesting-like protein, plays an essential role in chlorophyll and tocopherol biosynthesisRyouichi Tanaka, Maxi Rothbart, Seiko Oka, et al.
Leukemia Research|March 29, 2011
Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylationMasaru Shibata, Sachiko Ezoe, Kenji Oritani, et al.
Clinical Biochemistry|August 7, 2019
HbA1c adjusted by erythrocyte creatine is a useful glycemic control indicator in patients with hemolysisMasafumi Koga, Shinya Inada, Masaru Shibata, et al.
The Journal of Biological Chemistry|July 29, 2010
BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1Masahiro Tokunaga, Sachiko Ezoe, Hirokazu Tanaka, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Physical Review Letters|May 2, 2025
Accessing Universal Relations of Binary Neutron Star Waveforms in Massive Scalar-Tensor TheoryAlan Tsz-Lok Lam, Yong Gao, Hao-Jui Kuan, et al.
International Journal of Cardiology|July 6, 2016
Impact of postconditioning with lactate-enriched blood on in-hospital outcomes of patients with ST-segment elevation myocardial infarctionTakashi Koyama, Masahito Munakata, Takashi Akima, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 8, 2011
Hemostatic treatment using factor VIII concentrates for neutralizing high-responding inhibitors prior to CVAD insertion for immune-tolerance induction therapyMasaru Shibata, Takashi Nakagawa, Shinji Akioka, et al.
JACC. Case Reports|June 20, 2025
Discordant Antithrombotic Effects of Apixaban in Fibrillating Left Atria vs Post-Myocardial Infarction Left Ventricular AneurysmYusuke Yamazaki, Toru Egashira, Mayu Nozawa, et al.
Blood|May 16, 2002
A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivationKeiji Nogami, Midori Shima, Katsumi Nishiya, et al.
Stem Cells (Dayton, Ohio)|July 7, 2007
Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitorsHideto Matsui, Masaru Shibata, Brian Brown, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2010
LIL3, a light-harvesting-like protein, plays an essential role in chlorophyll and tocopherol biosynthesisRyouichi Tanaka, Maxi Rothbart, Seiko Oka, et al.
Leukemia Research|March 29, 2011
Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylationMasaru Shibata, Sachiko Ezoe, Kenji Oritani, et al.
Clinical Biochemistry|August 7, 2019
HbA1c adjusted by erythrocyte creatine is a useful glycemic control indicator in patients with hemolysisMasafumi Koga, Shinya Inada, Masaru Shibata, et al.
The Journal of Biological Chemistry|July 29, 2010
BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1Masahiro Tokunaga, Sachiko Ezoe, Hirokazu Tanaka, et al.
Pageof 5